A MULTI-STAKEHOLDER COLLABORATIVE APPROACH TO DEVELOPING A PATIENT-REPORTED OUTCOME MEASURE FOR FDA DRUG DEVELOPMENT TOOL QUALIFICATION- THE PRO CONSORTIUM’S DEPRESSION WORKING GROUP EXPERIENCE

Author(s)

Elizabeth Nicki Bush, MHS, Eli Lilly and Company, Indianapolis, USA; Wen-Hung Chen, PhD, U.S. Food and Drug Administration, Silver Spring, USA; Stephen Joel Coons, PhD, Critical Path Institute, Tucson, USA; Kelly P. McCarrier, PhD, MPH, Health Research Associates, Inc., Seattle, USA

PURPOSE: This workshop explores the benefits and challenges of a pre-competitive collaborative approach to the development of a patient-reported outcome (PRO) measure for drug development tool (DDT) qualification by the U.S. Food and Drug Administration (FDA) as a clinical outcome assessment (COA) measure for use in clinical trials. Using the experience of the PRO Consortium’s Depression Working Group (WG) at the Critical Path Institute (C-Path) as an example, challenges around communication, decision-making, and involvement of multiple stakeholders (e.g., pharmaceutical firms, C-Path, FDA) will be discussed. DESCRIPTION: Upon announcement of FDA’s COA Qualification Program, the Depression WG was one of the first multi-stakeholder collaborations formed (in 2009) to pursue qualification of a COA tool. The Depression WG’s goal was to qualify a PRO measure assessing symptoms of major depressive disorder (MDD) suitable for use as an efficacy endpoint measure in MDD treatment trials. Critical tasks faced by the Depression WG and FDA included navigating the new qualification process, interpreting the DDT Qualification Guidance, managing interactions, and developing streamlined communication processes among multiple stakeholders. Discussion leaders will review the evolution of the FDA COA Qualification Program and describe process improvements and enhanced communication approaches identified. These led to a more effective collaboration with all stakeholders committed to the goal of qualifying a new PRO measure: the Symptoms of Major Depressive Disorder Scale. Specific discussion topics include: rationale for developing a new PRO measure; the development process; lessons learned; and the evolution of the qualification process since 2009. Specific successes and redirection along the way will be highlighted during an open discussion of what might be done differently if starting the process today. Throughout the workshop, discussion leaders will encourage attendees to share experiences and perspectives on the qualification process, so collective recommendations can be made to guide future efforts of this kind.

Conference/Value in Health Info

2017-05, ISPOR 2017, Boston, MA, USA

Code

W22

Topic

Methodological & Statistical Research, Patient-Centered Research

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×